|
|
||||||||
CUTTING EDGE |



*
Pulmonary and Critical Care Medicine Division, Department of Internal Medicine,
Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor MI 48109; and
Department of Biological Sciences, Wayne State University, Detroit, MI 48202
| Abstract |
|---|
|
|
|---|
2 integrin complement receptor 3 (CR3), another
uPAR-binding adhesion protein, had no effect. Similarly, fucoidan, a
sulfated polysaccharide that binds to L-selectin CBD, inhibited the
Ca2+ signal. We conclude that uPAR associates with the CBD
region of L-selectin to form a functional signaling
complex. | Introduction |
|---|
|
|
|---|
2 integrin
complement receptor 3 (CR3) (CD11b/CD18), and superoxide release
(5, 6). In most respects, the results of uPAR aggregation
were quite dissimilar to those elicited by binding uPA to uPAR. One of
the lingering questions regarding cellular activation through uPAR
relates to its linkage to the plasma membrane by a
glycosylphosphatidylinositol (GPI) anchor (7). Absent any
direct connection to the cell interior, uPAR must use more circuitous
means to access intracellular signaling. To accomplish this, it forms
lateral associations with an array of membrane-spanning proteins,
including
2 integrins (7, 8).
Prior work has demonstrated a trimeric signaling complex in PMN
comprised of uPA, uPAR, and CR3 (9). Given the
distinctions between the effects of uPAR aggregation vs monomeric
uPA-uPAR coupling, we sought to determine whether uPAR aggregation
involved partner proteins other than
2
integrins.
L-selectin (CD62L) is an adhesion protein that participates in the
initial capture of flowing leukocytes and rolling adhesion along the
vascular endothelium (10). Its endothelial counterligands
principally include carbohydrate structures decorated with sialyl Lewis
X, although other ligands have been described (11). We
hypothesized that L-selectin would be a candidate uPAR signaling
partner because 1) the two proteins aggregate in general proximity to
each other during PMN adhesion, 2) L-selectin engagement induces
signaling events that resemble those elicited by uPAR aggregation, and
3) L-selectin has a carbohydrate binding domain (CBD) that plausibly
could interact with heavily glycosylated uPAR (7, 12, 13). | Materials and Methods |
|---|
|
|
|---|
Purified murine IgG Fc fragments were obtained from Jackson ImmunoResearch (West Grove, PA). Anti-human uPAR mAb (clone 3B10), anti-CD14 mAb (clone 26ic), and integrin mAbs were provided by Robert F. Todd III (University of Michigan Health System, Ann Arbor, MI). Hybridoma cells (3B10) were cultured in vitro, and the IgG2a mAb was purified by protein A-Sepharose (Ab Solutions, Palo Alto, CA). This mAb recognizes an epitope near the uPA binding site, and thus preferentially binds to unoccupied uPAR (6). mAbs were biotinylated with Sulfo-NHS-LC-biotin according to manufacturers directions (100 µg biotin/mg IgG; Pierce, Rockford, IL). The Dreg-56 hybridoma was obtained from the American Type Culture Collection (Manassas, VA), cultured in vitro (INTEGRA CELLine CL 1000; Integra Biosciences, Ijamsville, MD), and the mAb (IgG1), reactive against the CBD of human L-selectin, was purified with protein A-Sepharose. FITC and tetramethylrhodamineisothiocyanate (TRITC) were obtained from Molecular Probes (Eugene, OR). mAbs were dialyzed (0.15 M carbonate-bicarbonate buffer, pH 9.3, for 16 h at 4°C) and incubated with dyes at a fluorochrome-protein ratio of 40 µg TRITC or 30 µg FITC per mg protein at 25°C for 4 h. The fluorescent conjugates were then separated from unreacted fluorochromes by Sephadex G-25 column chromatography (Sigma, St. Louis, MO). Purified conjugates were dialyzed against PBS at pH 7.4 for 16 h at 4°C.
Purification and stimulation of human PMN
Peripheral blood was obtained from healthy volunteers according to provisions of the University of Michigan Institutional Review Board for Human Subject Research. PMN were isolated to >95% purity by sedimentation in 6% dextran in Ca2+/Mg2+-free PBS, followed by hypotonic lysis of RBCs with H2O for 30 s and centrifugation through Ficoll-Paque (Amersham Pharmacia Biotech, Piscataway, NJ). To cross-link uPAR, cells were suspended in experimental buffer (145 mM NaCl/5 mM KCl/1 mM MgCl2/10 mM glucose/1 mM CaCl2/1% w/v BSA/10 mM HEPES, pH 7.4). Cells were first incubated with murine IgG Fc fragments (150 µg/ml) at 4°C for 15 min to block binding of primary mAbs to Fc receptors. The effectiveness of this blocking step has been demonstrated previously (6). Cells were then incubated with biotinylated anti-uPAR mAb (100 µg/ml) at 4°C for 30 min and washed in experimental buffer. To initiate receptor cross-linking, goat anti-biotin Ab (100 µg/ml; Sigma) was added after warming the cells to 37°C. Previous studies using immunofluorescence microscopy have demonstrated that essentially identical protocols for Ab-mediated uPAR cross-linking in human PMN will produce receptor capping in approximately one-half of labeled cells (9).
Fluorescence microscopy
An axiovert-inverted fluorescence microscope with HBO-100 mercury illumination (Carl Zeiss, New York, NY) interfaced to a Dell 410 workstation via Scion SG-7 video card (Vay Tek, Fairfield, IA) was used. Fluorescence images were collected with an intensified charge-coupled device camera. A narrow bandpass-discriminating filter set was used with excitation at 485DF20 nm and emission of 530DF30 nm for FITC. For rhodamine, an excitation of 540DF20 nm and an emission of 590DF30 nm were used (Omega Optical, Brattleboro, VT). Long-pass dichroic mirrors at 510 and 560 nm were used for FITC and rhodamine, respectively. For energy transfer imaging, the 485DF22, 510LP, and 590DF30 filter combination was used (14).
Single-cell spectra were obtained using a imaging spectrophotometer system (14, 15). Labeled cells were illuminated with an excitation filter at 485DF22 nm and a 510LP dichroic mirror for FITC and resonance energy transfer (RET) experiments. For rhodamine emission spectra, excitation was provided with a 540DF20 nm filter and a 560LP dichroic mirror. The emission spectra were obtained with an Acton-150 (Acton Research, Acton, MA) imaging spectrophotometer fiber-optically coupled to a microscope. The exit port of the spectrophotometer was attached to a Gen-II intensifier coupled with an I-MAX-512 camera (Princeton Instruments, Trenton, NJ). Spectra collection was controlled by a high-speed Princeton ST-133 interface and a Stanford Research Systems DG-535 delay-gate generator (Sunnyvale, CA) and analyzed with Winspec software (Princeton Instruments).
Measurement of intracellular calcium concentration ([Ca2+]i)
Cells were loaded (5 x 106/ml) with the Ca2+-sensitive fluorescent dye Fluo-3/AM (2 µM; Molecular Probes) at 30°C for 30 min in 145 mM NaCl/5 mM KCl/1 mM MgCl2/10 mM glucose/4 mM probenecid/10 mM HEPES, pH 7.4. After pretreatment with Abs as indicated, 2.5 x 106 cells were suspended in 1 ml incubation buffer and prewarmed to 37°C. Fluorescence intensities were then measured with a SLM8000 spectrofluorometer equipped with SLM Spectrum Processor v3.5 software (SLM Instruments, Urbana, IL) using a 1 cm light path cuvette at an excitation wavelength of 505 nm and an emission wavelength of 530 nm. Fluorescence intensities were acquired at 2-s intervals for 300 s with continuous stirring of the cell suspension. These measurements were converted to nanomolar concentrations of [Ca2+]i by the calibration method of Grynkiewycz et al. (16), using a Kd for Fluo-3 of 864 nM (17).
Statistical analysis
Multiple comparisons were performed with one-way ANOVA with Dunnetts post test for multiple comparisons to a single control. All analyses were performed with GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA).
| Results and Discussion |
|---|
|
|
|---|
2 integrins CR3
(CD11b/CD18) and CR4 (CD11c/CD18), also demonstrated by RET. In various
cell types, uPAR is also found in other assemblies containing, among
other proteins, LFA-1, src kinases,
1 and
3 integrins, caveolin,
mannose-6-phosphate/insulin-like growth factor II-receptor, casein
kinase, and nucleolin (7, 8, 19, 20, 21, 22).
|
-chain (clones 44 and OKM1), the common
2 chain (clone TS1/18), and the CR4
-chain
(clone 3.9) did not significantly affect the Ca2+
flux induced by uPAR aggregation. The effect of the anti-L-selectin
mAb was also specific in that it had no comparable effects (at 50
µg/ml) on Ca2+ mobilization induced by the
chemotactic peptide FMLP (5 x 10-7 M;
97.9 ± 19.3% control, n = 3). Notably, this
signaling pathway is clearly distinct from the one previously defined
by binding uPA to uPAR, which induces a Ca2+
signal in PMN through an obligate association with CR3
(9). This further emphasizes that uPAR aggregation is a
highly distinct signaling mechanism from monomeric occupancy with
ligand uPA, both in the pathways engaged downstream and in the
composition of the signaling complex. Previously, we demonstrated that
uPAR regulates CR3-mediated adhesion to immobilized counterligands,
implying that this is due to uPAR binding directly to CR3
(2). Now, further work will be necessary to address the
possibility that uPAR also affects CR3 adhesiveness indirectly by
regulating CR3 activation through L-selectin engagement
(24). It will be important to determine whether there is a
dynamic competition between L-selectin and other partner proteins for
access to uPAR. Certainly, functioning as a signaling partner for
both L-selectin and
2 integrins broadens the
potential influence of uPAR on leukocyte recruitment. It will also be
important to know how uPAR forms aggregates. uPAR may draw into
clusters by binding directly to its own counterligands (uPA,
vitronectin) immobilized on cell surfaces or extracellular matrices.
Alternatively, uPAR may be aggregated passively by associating
with its partner proteins (L-selectin, integrins) as they form
clusters. Recent evidence also indicates that soluble uPAR
spontaneously forms dimers and oligomers but it is not known
whether this occurs on cell surfaces (27).
|
|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Robert G. Sitrin, University of Michigan, Pulmonary and Critical Care Medicine Division, 6301 MSRB III, Box 0642, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0642. ![]()
3 Abbreviations used in this paper: uPAR, urokinase plasminogen activator receptor; uPA, urokinase plasminogen activator; PMN, polymorphonuclear neutrophil(s); CR3, complement receptor 3; CBD, carbohydrate binding domain; TRITC, tetramethylrhodamineisothiocyanate; RET, resonance energy transfer. ![]()
Received for publication January 25, 2001. Accepted for publication February 26, 2001.
| References |
|---|
|
|
|---|
RIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164:953.
2 integrins, and src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1381.
1. Eur. J. Immunol. 29:1004.[Medline]
2-integrin. J. Immunol. 155:1502.[Abstract]
This article has been cited by other articles:
![]() |
S. Zhu, C. L. Gladson, K. E. White, Q. Ding, J. Stewart Jr., T. H. Jin, H. A. Chapman Jr., and M. A. Olman Urokinase receptor mediates lung fibroblast attachment and migration toward provisional matrix proteins through interaction with multiple integrins Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L97 - L108. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Sitrin, S. L. Emery, T. M. Sassanella, R. A. Blackwood, and H. R. Petty Selective Localization of Recognition Complexes for Leukotriene B4 and Formyl-Met-Leu-Phe within Lipid Raft Microdomains of Human Polymorphonuclear Neutrophils J. Immunol., December 1, 2006; 177(11): 8177 - 8184. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Selleri, N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization Blood, March 1, 2005; 105(5): 2198 - 2205. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Sitrin, D. R. Johnson, P. M. Pan, D. M. Harsh, J. Huang, H. R. Petty, and R. A. Blackwood Lipid Raft Compartmentalization of Urokinase Receptor Signaling in Human Neutrophils Am. J. Respir. Cell Mol. Biol., February 1, 2004; 30(2): 233 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, H. Kim, X. Cai, J. M. Lopez-Guisa, P. Carmeliet, and A. A. Eddy Urokinase Receptor Modulates Cellular and Angiogenic Responses in Obstructive Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1234 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Green, D. N. Pearson, N. B. Christensen, and S. I. Simon Topographic requirements and dynamics of signaling via L-selectin on neutrophils Am J Physiol Cell Physiol, March 1, 2003; 284(3): C705 - C717. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Leksa, S. Godar, M. Cebecauer, I. Hilgert, J. Breuss, U. H. Weidle, V. Horejsi, B. R. Binder, and H. Stockinger The N Terminus of Mannose 6-Phosphate/Insulin-like Growth Factor 2 Receptor in Regulation of Fibrinolysis and Cell Migration J. Biol. Chem., October 18, 2002; 277(43): 40575 - 40582. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Teofili, M. Martini, M. Luongo, A. Di Mario, G. Leone, V. De Stefano, and L. M. Larocca Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia J. Clin. Oncol., October 15, 2002; 20(20): 4249 - 4254. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Eddy Plasminogen activator inhibitor-1 and the kidney Am J Physiol Renal Physiol, August 1, 2002; 283(2): F209 - F220. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Feng, M. G. Tonnesen, E. I. B. Peerschke, and B. Ghebrehiwet Cooperation of C1q Receptors and Integrins in C1q-Mediated Endothelial Cell Adhesion and Spreading J. Immunol., March 1, 2002; 168(5): 2441 - 2448. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Gyetko, S. Sud, J. Sonstein, T. Polak, A. Sud, and J. L. Curtis Cutting Edge: Antigen-Driven Lymphocyte Recruitment to the Lung Is Diminished in the Absence of Urokinase-Type Plasminogen Activator (uPA) Receptor, but Is Independent of uPA J. Immunol., November 15, 2001; 167(10): 5539 - 5542. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |